Case Based Roundtable Logo

This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.

Experts Discuss the RCC Landscape and Available Therapy for Patients

Factors Influencing Frontline Therapy Options for Favorable-Risk RCC
Factors Influencing Frontline Therapy Options for Favorable-Risk RCC
January 09, 2023
Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.
Current and Potential Second-Line Therapies Following IO/TKI in RCC
Current and Potential Second-Line Therapies Following IO/TKI in RCC
November 11, 2022
Bradley A. McGregor, MD, discusses current and future second-line therapy options following frontline tyrosine kinase inhibitor and immunotherapy for patients with advanced renal cell carcinoma.
Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC
Long-Term Cabozantinib/Nivolumab Data Show Improved Survival in RCC
October 17, 2022
Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.
Ongoing Trials Investigate Intensified Frontline Therapy for RCC
Ongoing Trials Investigate Intensified Frontline Therapy for RCC
September 26, 2022
Bradley A. McGregor, MD, discusses new trials of intensified combination regimens for frontline treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma.
Recommendations for Treating Non–Clear Cell RCC
Recommendations for Treating Non–Clear Cell RCC
August 19, 2022
Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.
Key Considerations for Selecting Frontline Therapy in Advanced RCC
Key Considerations for Selecting Frontline Therapy in Advanced RCC
June 24, 2022
Naomi B. Haas, MD, discusses how patient characteristics and preference influence the choice of frontline treatment for advanced clear cell renal cell carcinoma.